§ 01 Overview
Overview
Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide.
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
§ 02 Mechanism
Mechanism of action
Orforglipron binds the GLP-1 receptor as a non-peptide small molecule. Unlike oral semaglutide, it does not require a protective absorption enhancer or fasted administration.
- 01Convenient oral daily dosing
- 02Weight loss comparable to injectable GLP-1s in Phase II
- 03Potential for broader access given oral form
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 7 – 45 mg daily
- Starting Dose
- 3 mg daily
- Route
- Oral
- Timing
- Any time
- Frequency
- Daily
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Phase III ACHIEVE program read out in 2024–2025 with strong efficacy signals.
FDA Status
Investigational. Filed with FDA in 2025.
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Eli Lilly's New GLP-1 Pill Orforglipron (Foundayo) Explained | Why It's NOT Just Oral Zepbound Kawartha Dairy Tragically Hip Ice Cream (hSvz4I7qzg) - Mshale
Eli Lilly's New GLP-1 Pill Orforglipron (Foundayo) Explained | Why It's NOT Just Oral Zepbound Kawartha Dairy Tragically Hip Ice Cream (hSvz4I7qzg) Mshale
Orforglipron pill beats oral semaglutide in major diabetes trial - diabetes.co.uk
Orforglipron pill beats oral semaglutide in major diabetes trial diabetes.co.uk
Orforglipron vs. Tirzepatide: What Are the Major Differences? - GoodRx
Orforglipron vs. Tirzepatide: What Are the Major Differences? GoodRx
Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment - 2 Minute Medicine
Foundayo (Orforglipron) Approval Marks the Beginning of the Oral GLP-1 Era for Obesity Treatment 2 Minute Medicine
What to Know About Foundayo, the New Pill GLP-1 for Weight Loss - US News Health
What to Know About Foundayo, the New Pill GLP-1 for Weight Loss US News Health
New weight loss pill beats oral Ozempic in major trial - ScienceDaily
New weight loss pill beats oral Ozempic in major trial ScienceDaily
Race to launch weight-loss pills heats up as smaller players advance - Reuters
Race to launch weight-loss pills heats up as smaller players advance Reuters
Semaglutide vs. Tirzepatide vs. Orforglipron for Weight Loss - US News Health
Semaglutide vs. Tirzepatide vs. Orforglipron for Weight Loss US News Health
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02Diarrhea
- 03Constipation
Contraindications
None specified.
§ 10 Questions
Oral GLP Compound (ER-ORF) FAQ
- What is Oral GLP Compound (ER-ORF)?
- Non-peptide oral GLP-1 agonist in late Phase III trials, offering daily pill dosing without the restrictions of oral semaglutide. Orforglipron binds the GLP-1 receptor as a non-peptide small molecule. Unlike oral semaglutide, it does not require a protective absorption enhancer or fasted administration.
- What is Oral GLP Compound (ER-ORF) used for?
- Reported uses include convenient oral daily dosing, weight loss comparable to injectable glp-1s in phase ii, and potential for broader access given oral form. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Oral GLP Compound (ER-ORF) dosed?
- Commonly referenced dosing is 7 – 45 mg daily, administered Oral. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Oral GLP Compound (ER-ORF)?
- Commonly reported side effects include nausea, diarrhea, and constipation. This list is not exhaustive.
- Is Oral GLP Compound (ER-ORF) legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Investigational. Filed with FDA in 2025..